The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal’s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians.

Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.

The Journal of Clinical Lipidology is NOW INCLUDED IN MEDLINE/PUBMED!

Electronic usage:
An increasing number of readers access the journal online via ScienceDirect, one of the world’s most advanced web delivery systems for scientific, technical and medical information.

Average monthly article downloads for this journal: 6,615*

* Figure is a monthly average of full-text articles downloaded from ScienceDirect in 2014

AUDIENCE

Medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. Cardiologists, endocrinologists, primary care physicians,
pharmacists, nurses, dietitians and those involved in the treatment of diabetes, hypertension and obesity.

**ABSTRACTING AND INDEXING**

Embase
Scopus
Journal Citation Reports - Science Edition
PubMed/Medline
PubMed/Medline

**EDITORIAL BOARD**

*Editors-in-Chief*

P. B. Duell, Oregon Health & Science University Knight Cardiovascular Institute and Division of Endocrinology, Diabetes, and Clinical Nutrition, Portland, Oregon, United States of America

K. C. Maki, MB Clinical Research and Consulting LLC, Addison, Illinois, United States of America

*Executive Editor*

M. R. Dicklin, MB Clinical Research and Consulting LLC, Addison, Illinois, United States of America

*Deputy Editors*

W. E. Boden, VA Boston Healthcare System, West Roxbury, Massachusetts, United States of America
Section Specialty: Epidemiology, Clinical trials, Preventive Cardiology

J. R. Guyton, Duke University Medical Center, Durham, North Carolina, United States of America
Section Specialty: Lipidology, Atherosclerosis, Endocrinology

*Associate Editors*

Z. Ahmad, The University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
Section Specialty: Internal Medicine, Endocrinology

E. A. Brinton, Utah Lipid Center, Salt Lake City, Utah, United States of America
Section Specialty: Lipidology

W. V. Brown, Emory University School of Medicine, Atlanta, Georgia, United States of America
Section Specialty: Lipoprotein Metabolism, Clinical Lipidology

A. Cuevas, Center for Advanced Metabolic Medicine and Nutrition (CAMMYN), Santiago, Chile
Section Specialty: Obesity, Nutrition, Atherosclerosis, Dyslipidemias

D. DeSilvey, Blue Hill Cardiovascular Medicine, Blue Hill, Maine, United States of America
Section Specialty: Cardiovascular Medicine

D. L. Dixon, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, United States of America
Section Specialty: Pharmacotherapy, Cardiometabolic Disease, Health Outcomes Research

J. M. Falko, University of Colorado Denver, Denver, Colorado, United States of America
Section Specialty: Endocrinology, Metabolism, Diabetes

D. Gaudet, University of Montreal, Montréal, Québec, Canada
Section Specialty: Hypertriglyceridemia, Genetic Lipid Disorders, Cardiometabolic Risk

E. A. Gill, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States of America
Section Specialty: Cardiology

I. Goldberg, New York University Grossman School of Medicine, New York, New York, United States of America
Section Specialty: Basic Lipid Physiology, Lipolytic Enzymes

M. Harada-Shiba, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
Section Specialty: Lipidology, Molecular Biology, Lipid Lowering Drugs, Familial Hypercholesterolemia

R. A. Hegele, Western University, London, Ontario, Canada
Section Specialty: DNA analysis, Dyslipoproteinemia, Endocrinology, Metabolism

L. C. Hemphill, Massachusetts General Hospital, Boston, Massachusetts, United States of America
Section Specialty: Clinical Trials, Familial hypercholesterolemia, LDL apheresis

T. A. Jacobson, Emory University School of Medicine, Atlanta, Georgia, United States of America
Section Specialty: Epidemiology, Disease Prevention, Clinical Trials

W. G. Jerome, Vanderbilt University, Nashville, Tennessee, United States of America
Section Specialty: Pathology, Microbiology, Immunology

D. Kalra, University of Louisville, Louisville, Kentucky, United States of America
Section Specialty: Risk Assessment, High-risk Populations, Guidelines, Atherosclerosis Imaging
W. Karmally, Columbia University, New York, New York, United States of America
Section Specialty: Women and Heart disease, Prevention Cardiology, Nutrition

R. M. Krauss, Children's Hospital Oakland Research Institute, Oakland, California, United States of America
Section Specialty: Endocrinology, Metabolism

R. La Forge, U.S. Indian Health Service, Division of Diabetes Treatment and Prevention, Durham, North Carolina, United States of America
Section Specialty: Diabetes

B. Lamarche, Laval University, Centre NUTRISS, Québec City, Quebec, Canada
Section Specialty: Nutrition, Dietary intervention, Epidemiology

E. V. Lerma, University of Illinois Chicago College of Medicine, Chicago, Illinois, United States of America
Section Specialty: Diabetes, Lipidology, Nephrology

M. Lopes-Virella, Medical University of South Carolina, Charleston, South Carolina, United States of America
Section Specialty: Diabetes, Immunology

R. H. Mackey, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
Section Specialty: Epidemiology

M. J. Malloy, University of California San Francisco, San Francisco, California, United States of America
Section Specialty: Pediatric Lipidology, Genetics, Lipoproteins

S. S. Martin, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America
Section Specialty: Cardiovascular Risk Assessment, Dyslipidemia

K. S. Petersen, The Pennsylvania State University - University Park Campus, University Park, Pennsylvania, United States of America
Section Specialty: Nutrition, CVD and Diabetes Prevention

J. Plutzky, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
Section Specialty: Cardiovascular Disease, Lipid Disorders, Vascular Medicine

G. S. Pokrywka, Baltimore, Maryland, United States of America
Section Specialty: Clinical Lipidology, Advanced Lipid Protein Testing, Women's Health, Menopause

J. Q. Purnell, Oregon Health & Science University, Division of Cardiovascular Medicine, Portland, Oregon, United States of America
Section Specialty: Endocrinology, Diabetes, Lipids, Obesity

A. T. Remaley, National Institutes of Health, Bethesda, Maryland, United States of America
Section Specialty: Atherosclerosis and Inflammation

G. Reyes-Soffer, Columbia University Irving Medical Center, New York, New York, United States of America
Section Specialty: Lipid and Lipoprotein Metabolism

R. D. Santos, University of Sao Paulo Medical School, São Paulo, Brazil
Section Specialty: Familial Hypercholesterolemia, Imaging in Atherosclerosis, Preventive Cardiology

D. E. Soffer, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America
Section Specialty: Clinical Lipidology, Familial Hypercholesterolemia

P. P. Toth, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
Section Specialty: Lipidology, Preventive Cardiology

G. L. Vega, The University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
Section Specialty: Clinical Nutrition

K. Vijayaraghavan, Arizona Heart Foundation; The University of Arizona, Tucson, Arizona, United States of America
Section Specialty: Lipidology, Heart Failure, Diabetes, Cardiorenal Connectome

S. S. Virani, The Aga Khan University, Karachi, Pakistan
Section Specialty: Cardiovascular Outcomes and Guidelines

G. F. Watts, The University of Western Australia Medical School, Perth, Australia
Section Specialty: Pharmacology, Cardiometabolic Medicine

A. S. Wierzbicki, Guy's and St Thomas' Hospitals, London, United Kingdom
Section Specialty: Lipidology, Pharmacology, Preventive Cardiology

R. A. Wild, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
Section Specialty: Reproductive Endocrinology, Women’s Health

K. Willard, Ascension SE Wisconsin Hospital Franklin Campus, Franklin, Wisconsin, United States of America
Section Specialty: Clinical Lipidology, ASCVD Risk Stratification, High Risk Populations, Clinical Trial Impact

D. P. Wilson, Cook Children's Medical Center, Fort Worth, Texas, United States of America
Section Specialty: Pediatric Lipid Management

N. D. Wong, University of California Irvine, Irvine, California, United States of America
Section Specialty: Epidemiology, Metabolic Syndrome, Diabetes, Dyslipidemia, Risk Stratification, Preventive Cardiology, Imaging

A. Zambon, University of Padua, Department of Medicine, Padova, Italy
Section Specialty: Endocrinology, Metabolism, Nutrition

Editorial Board
N. Abate, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America
R. Block, University of Rochester Medical Center, Rochester, New York, United States of America
M. B. Boffa, The University of Western Ontario, London, Ontario, Canada
L. T. Braun, Rush University, Chicago, Illinois, United States of America
W. C. Cromwell, Lipoprotein and Metabolic Disorders Institute, PLLC, Raleigh, North Carolina, United States of America
M. B. Elam, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America
E. A. Fisher, New York University Grossman School of Medicine, New York, New York, United States of America
J. S. Freeman, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, United States of America
A. Gotto Jr., Weil Cornell Medicine, New York, New York, United States of America
L. K. Jones, Geisinger Health, Danville, Pennsylvania, United States of America
D. G. Karalis, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States of America
S. M. Marcovina, Medpace Central Laboratories, Cincinnati, Ohio, United States of America
C. J. McNeal, Baylor Scott & White Medical Center, Temple, Texas, United States of America
M. Miller, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
P. M. Moriarty, The University of Kansas Medical Center, Kansas City, Kansas, United States of America
P. Morris, Medical University of South Carolina, Charleston, South Carolina, United States
S. Nash, Boulder, Colorado, United States of America
C. E. Orringer, NCH Rooney Heart Institute, Naples, Florida, United States of America
S. B. Patel, University of Cincinnati, Cincinnati, Ohio, United States of America
D. Rader, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
A. Rohatgi, The University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
J. Ross, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
M. D. Shapiro, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America
S. Shugg, Robert Wood Johnson Health System And RWJ Health Network, West Orange, New Jersey, United States of America
A. D. Sniderman, McGill University Health Centre, Montréal, Quebec, Canada
L. Sperling, Emory University, Atlanta, Georgia, United States of America
J. H. Stein, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
M. T. Sweeney, Emory University, Atlanta, Georgia, United States of America
J. A. Underberg, NYU Langone Health, New York, New York, United States of America
B. A. Warden, Oregon Health & Science University, Portland, Oregon, United States of America
G. R. Warnick, Prismhealthdx Inc, Austin, Texas, United States of America
P. J. Weinstock, Cooper University Hospital, Cooper Medical School, Camden, New Jersey, United States of America
P. W. Wilson, Emory University, Atlanta, Georgia, United States of America

Managing Editor
D. Newcombe, Boston, Massachusetts, United States of America

Society Liaison
D. Sayre, Jacksonville, Florida, United States of America
GUIDE FOR AUTHORS

Your Paper Your Way
We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.
To find out more, please visit the Preparation section below.

INTRODUCTION
The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism.

Journal of Clinical Lipidology provides rapid online electronic and print publication of the most important current scientific developments in the field of lipids and lipidology. The Journal publishes both clinical and basic original, peer-reviewed articles devoted to diagnosis and treatment of human lipid disorders. Original research reported in the Journal must include specimens or data from humans; studies exclusively in animals or cell culture are not accepted. Sections of the Journal address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.

Authors should consult appropriate EQUATOR reporting guidelines at equator-network.org. Particularly for randomized trials, observational studies, and systematic reviews or meta-analyses, appropriate checklists should be submitted, either accompanying the cover letter (not to be published) or as supplementary material (to be published online).

Manuscript Categories

Original Articles References should be limited articles generally should range between 2000 and 6000 words, and include no more than 40 references. Abstract, article structure, and optional supplementary (online only) material are described under Preparation requirements below.

Case Studies Case studies are limited to 4 authors, 8 double-spaced pages total, including text, references (no more than 20), figure legends, and 3 figures. Abstract (up to 160 words) is optional; see Preparation requirements below.

Reviews Contemporary and Historical Reviews (Solicited and Unsolicited). Review articles should contain a brief abstract (see Preparation requirements below) and generally should not exceed 5000 words, including references, tables, and figures. References should be limited to 60.

Editorial Commentaries All editorials by invitation only. Commentaries should be confined to articles in the current issue or a very specific topic that is current and of high interest to the readership.

Brief Communications Brief communications may reflect new concise findings of high value, clinical implementation science, or illustrative cases with concise review. They should not exceed 2000 words, including text, tables, figure legends, and up to 20 references. Total number of tables and figures is limited to 3. An unstructured abstract should be included, up to 160 words.

Letters to the Editor Letters should be double-spaced, not exceeding 450 words. No abstract. Letters will be reviewed and are subject to editing. If accepted for publication, a copy of the letter will be sent to the author(s) of the original article, if applicable. The author(s) will have an opportunity to respond with new material that will be considered for publication with the letter.

News and Statements from the NLA News and Statements from the NLA are only for the National Lipid Association (NLA) to provide content: NLA news and upcoming event information, as well as abstracts from the NLA Annual Scientific Sessions, scientific and consensus statements, and scientific forums held by chapters, when appropriate.
Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:
- E-mail address
- Full postal address

All necessary files have been uploaded:

Manuscript:
- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)

Further considerations
- Manuscript has been "spell checked" and "grammar checked"
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our Support Center.

BEFORE YOU BEGIN

Ethics in publishing
Please see our information on Ethics in publishing.

Studies in humans and animals
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Research Council's Guide for the Care and Use of Laboratory Animals and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double anonymized) or the manuscript file (if single anonymized). If there are no interests to declare then please state this:
'Declarations of interest: none'. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.

**Declaration of generative AI in scientific writing**
The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier’s AI policy for authors.

Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

**Disclosure instructions**
Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Use of AI and AI-assisted Technologies Statement’.

**Statement:** During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the placed in a new section entitled as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If AI has not been used in the writing process, please state that it has not been used.

**Submission declaration and verification**
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify compliance, your article may be checked by Crossref Similarity Check and other originality or duplicate checking software.

**Use of inclusive language**
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

**Reporting sex- and gender-based analyses**
**Reporting guidance**
For research involving or pertaining to humans, animals or eukaryotic cells, investigators should integrate sex and gender-based analyses (SGBA) into their research design according to funder/sponsor requirements and best practices within a field. Authors should address the sex and/or gender dimensions of their research in their article. In cases where they cannot, they should discuss this as a limitation to their research's generalizability. Importantly, authors should explicitly state what definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility of their research and to avoid ambiguity or conflation of terms and the constructs to which they refer (see Definitions section below). Authors can refer to the Sex and Gender Equity in Research (SAGER) guidelines and the SAGER guidelines checklist. These offer systematic approaches to the use and editorial review of sex and gender information in study design, data analysis, outcome reporting and research interpretation - however, please note there is no single, universally agreed-upon set of guidelines for defining sex and gender.

**Definitions**

Sex generally refers to a set of biological attributes that are associated with physical and physiological features (e.g., chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex categorization (male/female) is usually designated at birth ("sex assigned at birth"), most often based solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed roles, behaviors, and identities of women, men and gender-diverse people that occur in a historical and cultural context and may vary across societies and over time. Gender influences how people view themselves and each other, how they behave and interact and how power is distributed in society. Sex and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging whereas these constructs actually exist along a spectrum and include additional sex categorizations and gender identities such as people who are intersex/have differences of sex development (DSD) or identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important for authors to define the manner in which they are used. In addition to this definition guidance and the SAGER guidelines, the resources on this page offer further insight around sex and gender in research studies.

**Contributors**

Each author is required to declare their individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.

**Authorship**

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

**Changes to authorship**

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

**Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

Open access
Please visit our Open Access page for more information.

Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the Language Editing service available from Elsevier's Language Services.

Submission
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article

Previous presentation or release of information
A complete report following presentation at a meeting or publication of preliminary findings elsewhere (e.g. an abstract) can be considered. Media coverage of meeting presentations will not jeopardize consideration, but direct release of information through press releases or news media briefings may preclude consideration by the journal.

PREPARATION

NEW SUBMISSIONS
Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

References
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article
number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

**Formatting requirements**

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions. If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes. Divide the article into clearly defined sections.

**Figures and tables embedded in text**

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

**Peer review**

This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

**REVISED SUBMISSIONS**

**Use of word processing software**

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

**Article structure**

**Subdivision - unnumbered sections**

Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

**Introduction**

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

**Material and methods**

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

**Results**

Results should be clear and concise.

**Discussion**

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

**Conclusions**

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.
**Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**

- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

**Highlights**

Highlights are mandatory for this journal as they help increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the example Highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

**Abstract**

Please include a brief abstract (without references) of fewer than 250 words for Original Articles. Divide the abstract into sections: **Background, Objective, Methods, Results, and Conclusion** that states the importance and potential implications of the observations.

For Reviews and Case Studies, please follow the format instructions below:

- **Reviews:** (250 words) Background (justify relevance to readership), Sources of material, abstract of findings and conclusion.

- **Case Studies:** Brief of overview of the problem and major management decisions required to resolve the case.

**Graphical abstract**

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.

**Keywords**

Immediately after the abstract, list 5 to 10 key words, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

**Formatting of funding sources**

List funding sources in this standard way to facilitate compliance to funder's requirements:
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, it is recommended to include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Indicate per figure if it is a single, 1.5 or 2-column fitting image.
• For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
• Please note that individual figure files larger than 10 MB must be provided in separate source files.

A detailed guide on electronic artwork is available. You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
• Supply files that are too low in resolution.
• Submit graphics that are disproportionately large for the content.

Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.
**Figure captions**
Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

**Tables**
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

**Disclosure**
All manuscripts must contain a Declaration of Interest Statement, an Author Contribution Statement, a Use of AI and AI-assisted Technologies Statement, and an Ethical Statement. These statements should appear in in a separate disclosure section at the end of the article (just before the reference section). Please refer to the Information for authors packet for more details on these four statements.

**Declaration of Interest**
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests. If there are no interests to declare then please state this: 'Declarations of interest: none'.

**Author Contribution Statement**
Each author is required to declare their individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.

**Use of AI and AI-assisted Technologies Statement**
Authors must disclose the use of generative AI and AI-assisted technologies in the writing of the manuscript. Example Statement: During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication. If AI has not been used in the writing process, please state that it has not been used.

**Ethical Statement**
Manuscripts describing research involving human subjects must document both IRB approval/waiver and that informed consent was obtained from patients who served as subjects of the investigation. If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Research Council’s Guide for the Care and Use of Laboratory Animals and the authors should clearly indicate in the manuscript that such guidelines have been followed.

**References**
**Citation in text**
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.
Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Preprint references
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

Reference style
Number references in numerical order in the text. Include references to unpublished material or personal communications in the text in parentheses. Abbreviate titles of periodicals according to the style of Index Medicus, National Library of Medicine. List all authors in each reference following exactly the format and punctuation shown below.
Journal Article-Example

Chapter in Book with Different Author and Editor-Example

Please note that the Journal of Clinical Lipidology's reference style is now included in the EndNote® bibliographic system. Authors are responsible for the accuracy and completeness of their references and for correct text citation.

Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Video
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'still's with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Research data
This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings, which may also include software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

Data linking
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.
There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](http://www.elsevier.com/locate/jacl).

For **supported data repositories** a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**Data statement**

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](http://www.elsevier.com/locate/jacl).

**AFTER ACCEPTANCE**

**Online proof correction**

To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

**Offprints**

The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail (the PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use). For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication.

**AUTHOR INQUIRIES**

Visit the [Elsevier Support Center](http://www.elsevier.com/locate/jacl) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | [https://www.elsevier.com](https://www.elsevier.com)